Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442507 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00442507 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants.
The verdict
NCT00442507, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction
Interventions
- DRUG Erlotinib
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442507
The ClinicalTrials.gov registry entry for NCT00442507 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00442507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442507 about?
NCT00442507 is a clinical study titled "Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction". Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction
What is the current status of trial NCT00442507?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2007-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00442507?
The interventions under investigation include: Erlotinib (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00442507?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.